whatshot

LGNZZ   $0.1351  -15.56% Market Closed

Ligand Pharmaceuticals, Inc.
show_chart Advanced Chart of LGNZZ
Last Events:

2023-04-13 Trend pattern changed from не определен to расходящийся клин с наклоном вниз.

2023-04-13 Signal in Stochastic changed from не определен to bullish. The stochastic indicator is in the upper part of the neutral territory and it grows. These factors indicate that positive dynamics persists. Last signal: up-crossing the middle level.

2023-04-13 Signal in MACD changed from не определен to bearish. Oscillator MACD is in the negative territory it's lower than the signal line and falls. These factors mean that negative mood prevails. Last signal: main and signal line crossing.

2023-04-13 Signal in RSI changed from не определен to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: entrance to the overbought zone.

2023-04-13 Signal in EMA100 changed from не определен to n/a.

2023-04-13 Signal in EMA50 changed from не определен to bearish reversal. 2023-01-12 the price crossed down the moving average line and getting closer to the MA, which means that the short-term downside trend weakens.

2023-04-13 Signal in EMA20 changed from не определен to n/a. 2023-01-12 the price crossed down the moving average line and getting closer to the MA, which means that the short-term downside trend weakens.

2023-04-13 Trend Power changed from не определен to strong.

Current temperature:
ST: None, Cor:

Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Sell Sell -
rsi Sell - -
macd Sell Sell -
stoch Sell Sell -
ma20 - - -
ma50 - - -
ma100 Sell - -
ISIN US53220K1732
ceo Mr. Todd C. Davis Ph.D.
Website https://www.ligand.com
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.